HIF-2α, but not HIF-1α, mediates hypoxia-induced up-regulation of Flt-1 gene expression in placental trophoblasts

[1]  Y. Osuga,et al.  Enhanced HIF2α expression during human trophoblast differentiation into syncytiotrophoblast suppresses transcription of placental growth factor , 2017, Scientific Reports.

[2]  G. Matsuda,et al.  A Rho-associated coiled-coil containing kinases (ROCK) inhibitor, Y-27632, enhances adhesion, viability and differentiation of human term placenta-derived trophoblasts in vitro , 2017, PloS one.

[3]  T. Benzing,et al.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. , 2016, Journal of the American Society of Nephrology : JASN.

[4]  I. Konishi,et al.  Case of soluble fms‐like tyrosine kinase 1 apheresis in severe pre‐eclampsia developed at 15 weeks’ gestation , 2015, The journal of obstetrics and gynaecology research.

[5]  W. Liu,et al.  Study on the Expressions of PHD and HIF in Placentas from Normal Pregnant Women and Patients with Preeclampsia , 2014, International journal of biological sciences.

[6]  Rui Chen,et al.  Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules , 2013, Nature chemical biology.

[7]  M. Shibuya,et al.  Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. , 2013, Journal of biochemistry.

[8]  Cheng-Jun Hu,et al.  Upstream Stimulatory Factor 2 and Hypoxia-Inducible Factor 2α (HIF2α) Cooperatively Activate HIF2 Target Genes during Hypoxia , 2012, Molecular and Cellular Biology.

[9]  M. Ohh,et al.  The updated biology of hypoxia‐inducible factor , 2012, The EMBO journal.

[10]  M. Lappas,et al.  Placental expression of a novel primate‐specific splice variant of sFlt‐1 is upregulated in pregnancies complicated by severe early onset pre‐eclampsia , 2011, BJOG : an international journal of obstetrics and gynaecology.

[11]  Santosh A. Khedkar,et al.  Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2011, Circulation.

[12]  J. V. D. van der Post,et al.  Expression of Placental FLT1 Transcript Variants Relates to Both Gestational Hypertensive Disease and Fetal Growth , 2011, Hypertension.

[13]  M. Shibuya.  Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[14]  Y. Ishigaki,et al.  Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing , 2011, The Biochemical journal.

[15]  B. Huppertz,et al.  Placental and trophoblastic in vitro models to study preventive and therapeutic agents for preeclampsia. , 2011, Placenta.

[16]  C. Marsh,et al.  Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. , 2011, Blood.

[17]  R. Levine,et al.  Pathogenesis of preeclampsia. , 2010, Annual review of pathology.

[18]  Kang Z. Liu,et al.  A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  S. Lim,et al.  Preeclampsia: the role of angiogenic factors in its pathogenesis. , 2009, Physiology.

[20]  L. Florea,et al.  Novel splice variants of sFlt1 are upregulated in preeclampsia. , 2009, Placenta.

[21]  A. Jeyabalan,et al.  Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. , 2009, Placenta.

[22]  S. Yagel,et al.  A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.

[23]  J. Foidart,et al.  Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. , 2008, Human reproduction.

[24]  Kang Z. Liu,et al.  Intronic polyadenylation signal sequences and alternate splicing generate human soluble Fltl variants and regulate the abundance of soluble Flt1 in the placenta , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  G. Saade,et al.  The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. , 2007, American journal of obstetrics and gynecology.

[26]  G. Semenza,et al.  Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1* , 2006, Journal of Biological Chemistry.

[27]  M. Wood,et al.  Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. , 2006, Cancer research.

[28]  J. Kingdom,et al.  Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[29]  Y. Zhang,et al.  Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. , 2005, Placenta.

[30]  R. Ness,et al.  Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. , 2004, Placenta.

[31]  S. Kōzuma,et al.  Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.

[32]  Asif Ahmed,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004, Circulation research.

[33]  R. Nagai,et al.  Endothelial PAS Domain Protein 1 Gene Promotes Angiogenesis Through the Transactivation of Both Vascular Endothelial Growth Factor and Its Receptor, Flt-1 , 2004, Circulation research.

[34]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[35]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[36]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[37]  L. Weissfeld,et al.  Selective Overexpression of the Hypoxia-Inducible Transcription Factor, HIF-2α, in Placentas from Women with Preeclampsia , 2001 .

[38]  D. Charnock-Jones,et al.  Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. , 1999, Molecular endocrinology.

[39]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[40]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[41]  M. Shibuya,et al.  Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor‐1 (Flt‐1 Tyrosine Kinase) , 1997, Japanese journal of cancer research : Gann.

[42]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.